Susquehanna International Group, LLP Surface Oncology, Inc. Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.57 - $0.88 $21,622 - $33,381	37,934 Added 266.86%	52,149 $45,000
Q1 2023 May 16, 2023	SELL	$0.61 - $1.03 $21,716 - $36,668	-35,600 Reduced 71.46%	14,215 $9,000
Q4 2022 Feb 14, 2023	BUY	$0.62 - $1.21 $16,059 - $31,342	25,903 Added 108.33%	49,815 $40,000
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.1 $7,490 - $14,981	-7,134 Reduced 22.98%	23,912 $25,000
Q2 2022 Aug 15, 2022	SELL	$1.42 - $3.15 $3,292 - $7,304	-2,319 Reduced 6.95%	31,046 $51,000
Q1 2022 May 16, 2022	SELL	$2.65 - $5.08 $142,954 - $274,040	-53,945 Reduced 61.79%	33,365 $98,000
Q4 2021 Feb 14, 2022	BUY	$4.73 - $7.9 $252,250 - $421,307	53,330 Added 156.95%	87,310 $417,000
Q3 2021 Nov 15, 2021	SELL	$5.16 - $7.98 $384,652 - $594,869	-74,545 Reduced 68.69%	33,980 $258,000
Q2 2021 Aug 11, 2021	SELL	$6.45 - $9.09 $1.93 Million - $2.73 Million	-299,985 Reduced 73.43%	108,525 $810,000
Q1 2021 May 17, 2021	BUY	$7.25 - $13.82 $1.49 Million - $2.84 Million	205,705 Added 101.43%	408,510 $3.19 Million
Q4 2020 Feb 16, 2021	BUY	$6.87 - $10.48 $1.39 Million - $2.13 Million	202,805 New	202,805 $1.87 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.